FDA clears first contact lens with light-adaptive technology
Published: Apr 10, 2018
SILVER SPRING, Md., April 10, 2018 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today cleared the first contact lens to incorporate an additive that automatically darkens the lens when exposed to bright light. The Acuvue Oasys Contact Lenses with Transitions Light Intelligent Technology are soft contact lenses indicated for daily use to correct the vision of people with non-diseased eyes who are nearsighted (myopia) or farsighted (hyperopia). They can be used by people with certain degrees of astigmatism, an abnormal curvature of the eye.
The National Eye Institute at the National Institutes of Health estimates that 42 percent of Americans aged 12 to 54 have myopia and 5 to 10 percent of all Americans have hyperopia. The Centers for Disease Control and Prevention estimates that as of 2014, more than 40 million Americans were contact lens wearers.
"This contact lens is the first of its kind to incorporate the same technology that is used in eyeglasses that automatically darken in the sun," said Malvina Eydelman, director of the Division of Ophthalmic, and Ear, Nose and Throat Devices at the FDA's Center for Devices and Radiological Health.
The contact lenses contain a photochromic additive that adapts the amount of visible light filtered to the eye based on the amount of UV light to which they are exposed. This results in slightly darkened lenses in bright sunlight that automatically return to a regular tint when exposed to normal or dark lighting conditions.
For today's clearance, the FDA reviewed scientific evidence including a clinical study of 24 patients that evaluated daytime and nighttime driving performance while wearing the contact lenses. The results of the study demonstrated there was no evidence of concerns with either driving performance or vision while wearing the lenses.
Patients with the following conditions should not use these contact lenses: inflammation or infection in or around the eye or eyelids; any eye disease, injury or abnormality that affects the cornea, conjunctiva (the mucous membrane that covers the front of the eye and lines the inside of the eyelids) or eyelids; any previously diagnosed condition that makes contact lens wear uncomfortable; severe dry eye; reduced corneal sensitivity; any systemic disease that may affect the eye or be made worse by wearing contact lenses; allergic reactions on the surface of the eye or surrounding tissues that may be induced or made worse by wearing contact lenses or use of contact lens solutions; any active eye infection or red or irritated eyes.
These contacts are intended for daily wear for up to 14 days. Patients should not sleep in these contact lenses, expose them to water or wear them longer than directed by an eye care professional. These contacts should not be used as substitutes for UV protective eyewear.
The Acuvue Oasys Contact Lenses with Transitions Light Intelligent Technology were reviewed through the premarket notification 510(k) pathway. A 510(k) is a premarket submission made by device manufacturers to the FDA to demonstrate that the new device is substantially equivalent to a legally marketed predicate device.
The FDA granted clearance of the Acuvue Oasys Contact Lenses with Transitions Light Intelligent Technology to Johnson & Johnson Vision Care, Inc.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Media Inquiries: Angela Stark, 301-796-0397, email@example.com
Consumer Inquiries: 888-INFO-FDA
View original content with multimedia: http://www.prnewswire.com/news-releases/fda-clears-first-contact-lens-with-light-adaptive-technology-300627473.html
SOURCE U.S. Food and Drug Administration